Machine-learning derived identification of prognostic signature to forecast head and neck squamous cell carcinoma prognosis and drug response

被引:0
|
作者
Li, Sha-Zhou [1 ]
Sun, Hai-Ying [1 ]
Tian, Yuan [2 ]
Zhou, Liu-Qing [1 ]
Zhou, Tao [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Otorhinolaryngol, Wuhan, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Geriatr, Wuhan, Hubei, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
machine learning; HNSCC; DEGs; tumor microenvironment; immunotherapy; CETUXIMAB; RECURRENT;
D O I
10.3389/fimmu.2024.1469895
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction Head and neck squamous cell carcinoma (HNSCC), a highly heterogeneous malignancy is often associated with unfavorable prognosis. Due to its unique anatomical position and the absence of effective early inspection methods, surgical intervention alone is frequently inadequate for achieving complete remission. Therefore, the identification of reliable biomarker is crucial to enhance the accuracy of screening and treatment strategies for HNSCC.Method To develop and identify a machine learning-derived prognostic model (MLDPM) for HNSCC, ten machine learning algorithms, namely CoxBoost, elastic network (Enet), generalized boosted regression modeling (GBM), Lasso, Ridge, partial least squares regression for Cox (plsRcox), random survival forest (RSF), stepwise Cox, supervised principal components (SuperPC), and survival support vector machine (survival-SVM), along with 81 algorithm combinations were utilized. Time-dependent receiver operating characteristics (ROC) curves and Kaplan-Meier analysis can effectively assess the model's predictive performance. Validation was performed through a nomogram, calibration curves, univariate and multivariate Cox analysis. Further analyses included immunological profiling and gene set enrichment analyses (GSEA). Additionally, the prediction of 50% inhibitory concentration (IC50) of potential drugs between groups was determined.Results From analyses in the HNSCC tissues and normal tissues, we found 536 differentially expressed genes (DEGs). Subsequent univariate-cox regression analysis narrowed this list to 18 genes. A robust risk model, outperforming other clinical signatures, was then constructed using machine learning techniques. The MLDPM indicated that high-risk scores showed a greater propensity for immune escape and reduced survival rates. Dasatinib and 7 medicine showed the superior sensitivity to the high-risk NHSCC, which had potential to the clinical.Conclusions The construction of MLDPM effectively eliminated artificial bias by utilizing 101 algorithm combinations. This model demonstrated high accuracy in predicting HNSCC outcomes and has the potential to identify novel therapeutic targets for HNSCC patients, thus offering significant advancements in personalized treatment strategies.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Disulfidptosis features and prognosis in head and neck squamous cell carcinoma patients: unveiling and validating the prognostic signature across cohorts
    Hao Xue
    Qianyu Sun
    Heqing Zhang
    Hanxiao Huang
    Haowei Xue
    Journal of Cancer Research and Clinical Oncology, 150
  • [32] Disulfidptosis features and prognosis in head and neck squamous cell carcinoma patients: unveiling and validating the prognostic signature across cohorts
    Xue, Hao
    Sun, Qianyu
    Zhang, Heqing
    Huang, Hanxiao
    Xue, Haowei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (03)
  • [33] A Prognostic 5-lncRNA Expression Signature for Head and Neck Squamous Cell Carcinoma
    Guancheng Liu
    Jinyang Zheng
    Liming Zhuang
    Yunxia Lv
    Gangcai Zhu
    Leiming Pi
    Junchen Wang
    Changhan Chen
    Zhexuan Li
    Jiangyi Liu
    liangjuan Chen
    Gengming Cai
    Xin Zhang
    Scientific Reports, 8
  • [34] The Prognostic Value of the DNA Repair Gene Signature in Head and Neck Squamous Cell Carcinoma
    Ming, Ruijie
    Wang, Enhao
    Wei, Jiahui
    Shen, Jinxiong
    Zong, Shimin
    Xiao, Hongjun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Novel Prognostic Model Based on Immune Signature for Head and Neck Squamous Cell Carcinoma
    Wang, Yingying
    Xu, Yu
    Hua, Qingquan
    Jiang, Yang
    Liu, Peiqiang
    Zhang, Wei
    Xiang, Rong
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [36] Development and Validation of a Robust Immune Prognostic Signature for Head and Neck Squamous Cell Carcinoma
    Qiu, Yu
    Cui, Li
    Lin, Yang
    Gao, Bingju
    Li, Jun
    Zhao, Xinyuan
    Zhu, Xiaofeng
    Hu, Shen
    Lin, Lisong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [37] Validation of a Machine Learning Model to Predict Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
    Lee, Andrew Sangho
    Valero, Cristina
    Yoo, Seong-keun
    Vos, Joris L.
    Chowell, Diego
    Morris, Luc G. T.
    CANCERS, 2024, 16 (01)
  • [38] A Prognostic 5-IncRNA Expression Signature for Head and Neck Squamous Cell Carcinoma
    Liu, Guancheng
    Zheng, Jinyang
    Zhuang, Liming
    Lv, Yunxia
    Zhu, Gangcai
    Pi, Leiming
    Wang, Junchen
    Chen, Changhan
    Li, Zhexuan
    Liu, Jiangyi
    Chen, Iiangjuan
    Cai, Gengming
    Zhang, Xin
    SCIENTIFIC REPORTS, 2018, 8
  • [39] Machine learning-based prognostic modeling integrating PANoptosis in head and neck squamous cell carcinoma
    Chen Li
    Jiajing Lu
    Jialin Zhu
    Tao Zhou
    Qijie Shen
    Bikun Huang
    Qingsong Li
    Discover Oncology, 16 (1)
  • [40] A robust six-miRNA prognostic signature for head and neck squamous cell carcinoma
    Zhao, Xinyuan
    Cui, Li
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (11) : 8799 - 8811